Additionally, these GBM tissues are also further examined by immunostaining or sequencing for IDH mutations, O6-methylguanine methyltransferase (MGMT) methylation, and other prognostic biomarkers, which will be discussed in detail below [18,19]. This evidence concerns the gene IDH2 and glioblastoma.